<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922919</url>
  </required_header>
  <id_info>
    <org_study_id>API/2016/74</org_study_id>
    <nct_id>NCT03922919</nct_id>
  </id_info>
  <brief_title>Effect of Administration of 3rd Generation Cephalosporin on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (CEF-IMPACT)</brief_title>
  <acronym>CEF-IMPACT</acronym>
  <official_title>Effect of Administration of 3rd Generation Cephalosporin (Ceftriaxone Versus Cefotaxime) on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (EB C3G-R)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the frequency of occurrence of digestive carrying of 3rd
      generation cephalosporin-resistant enterobacteriaceae (EB C3G-R), acquired during
      hospitalization in one of the participating departments, between patients treated with
      ceftriaxone and patients treated with cefotaxime
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>stepped-wedge design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of occurrence of digestive carrying of EB C3G-R</measure>
    <time_frame>30 days after inclusion</time_frame>
    <description>Frequency of occurrence of digestive carrying of EB C3G-R</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence rate of EB C3G-R infections</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the effect of systematic use of cefotaxime rather than ceftriaxone on the incidence rate of EB C3G-R infections in participating departments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with occurrence of positive rectal swab with 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R)</measure>
    <time_frame>30 days after inclusion</time_frame>
    <description>Compare the number of patients with occurrence of positive rectal swab with 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R), 30 days after inclusion, between patients treated with ceftriaxone and patients treated with cefotaxime.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Infectious Disease - Resistant Enterobacteriaceae (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>Cefotaxime or ceftriaxone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>free use of cefotaxime or ceftriaxone by the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefotaxim group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systematic use of cefotaxime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefotaxime Injection</intervention_name>
    <description>Systematic use of cefotaxime.</description>
    <arm_group_label>Cefotaxim group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal swab</intervention_name>
    <description>Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion</description>
    <arm_group_label>Cefotaxim group</arm_group_label>
    <arm_group_label>Cefotaxime or ceftriaxone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefotaxime/ceftriaxone</intervention_name>
    <description>ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician</description>
    <arm_group_label>Cefotaxime or ceftriaxone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Indication for antibiotic treatment with a 3rd generation injectable cephalosporin
             (cefotaxime or ceftriaxone)

          -  Signed Informed Consent

        Exclusion Criteria:

          -  Hypersensitivity to ceftriaxone or cefotaxime, to another cephalosporin or to any of
             the excipients of the specialities concerned.

          -  History of severe hypersensitivity (e.g., anaphylactic reaction) to another class of
             antibacterial agent of the beta-lactam family (penicillins, monobactams and
             carbapenes)

          -  Subcutaneous administration of ceftriaxone

          -  Pregnant and breastfeeding woman

          -  Suspicion of Pseudomonas infection or documented Pseudomonas infection requiring
             ceftazidime treatment

          -  Suspicion of group III enterobacteriaceae infection or group III enterobacteriaceae
             infection requiring cefepime treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BOUILLER Kevin, Dr</last_name>
      <phone>0381219187</phone>
      <email>kbouiller@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

